Sample classification from protein mass spectrometry, by 'peak probability contrasts'

被引:141
作者
Tibshirani, R [1 ]
Hastie, T
Narasimhan, B
Soltys, S
Shi, GY
Koong, A
Le, QT
机构
[1] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Stat, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
关键词
D O I
10.1093/bioinformatics/bth357
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Motivation: Early cancer detection has always been a major research focus in solid tumor oncology. Early tumor detection can theoretically result in lower stage tumors, more treatable diseases and ultimately higher cure rates with less treatment-related morbidities. Protein mass spectrometry is a potentially powerful tool for early cancer detection. We propose a novel method for sample classification from protein mass spectrometry data. When applied to spectra from both diseased and healthy patients, the 'peak probability contrast' technique provides a list of all common peaks among the spectra, their statistical significance and their relative importance in discriminating between the two groups. We illustrate the method on matrix-assisted laser desorption and ionization mass spectrometry data from a study of ovarian cancers. Results: Compared to other statistical approaches for class prediction, the peak probability contrast method performs as well or better than several methods that require the full spectra, rather than just labelled peaks. It is also much more interpretable biologically. The peak probability contrast method is a potentially useful tool for sample classification from protein mass spectrometry data.
引用
收藏
页码:3034 / 3044
页数:11
相关论文
共 27 条
[11]   Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis [J].
Kozak, KR ;
Amneus, MW ;
Pusey, SM ;
Su, F ;
Luong, MN ;
Luong, SA ;
Reddy, ST ;
Farias-Eisner, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (21) :12343-12348
[12]  
Li JN, 2002, CLIN CHEM, V48, P1296
[13]  
Merchant M, 2000, ELECTROPHORESIS, V21, P1164, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1164::AID-ELPS1164>3.3.CO
[14]  
2-S
[15]  
NASON GP, 1998, WAVETHRESH3 SOFTWARE
[16]   Clinical proteomics: Translating benchside promise into bedside reality [J].
Petricoin, EF ;
Zoon, KC ;
Kohn, EC ;
Barrett, JC ;
Liotta, LA .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) :683-695
[17]   Use of proteomic patterns in serum to identify ovarian cancer [J].
Petricoin, EF ;
Ardekani, AM ;
Hitt, BA ;
Levine, PJ ;
Fusaro, VA ;
Steinberg, SM ;
Mills, GB ;
Simone, C ;
Fishman, DA ;
Kohn, EC ;
Liotta, LA .
LANCET, 2002, 359 (9306) :572-577
[18]  
Qu YS, 2002, CLIN CHEM, V48, P1835
[19]  
Rai AJ, 2002, ARCH PATHOL LAB MED, V126, P1518
[20]   American Cancer Society guidelines for the early detection of cancer, 2003 [J].
Smith, RA ;
Cokkinides, V ;
Eyre, HJ .
CA-A CANCER JOURNAL FOR CLINICIANS, 2003, 53 (01) :27-43